Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic

International Journal of Urology

Volumn 23, Issue 8, 2016, Pages 654-665

  Imamura, Yusuke ^a   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

androgen receptor; castration resistant prostate cancer; EPI 506; novel agents; prostate cancer; splice variants

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; APALUTAMIDE; ENZALUTAMIDE; EPI 506; GALETERONE; NICLOSAMIDE; ODM 201; PHOSPHATIDYLINOSITOL 3 KINASE; SEVITERONEL; STEROID RECEPTOR; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; BIOPSY; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CROSS RESISTANCE; CRYSTAL STRUCTURE; FEEDBACK SYSTEM; HUMAN; LIQUID BIOPSY; MALE; MOLECULAR IMAGING; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEQUENCE HOMOLOGY; TREATMENT RESPONSE;

EID: 84979609987     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.13137     Document Type: Review

References (140)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015; 65: 87–108.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J. Clin. 2015; 65: 5–29.
3. Buttigliero C, Tucci M, Bertaglia V et al. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat. Rev. 2015; 41: 884–92.
4. Debes JD, Tindall DJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett. 2002; 187: 1–7.
5. Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin. Chem. 2011; 57: 1366–75.
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001; 1: 34–45.
7. Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P. The hallmarks of castration-resistant prostate cancers. Cancer Treat. Rev. 2015; 41: 588–97.
8. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13: 983–92.
9. Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16: 152–60.
10. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012; 367: 1187–97.
11. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014; 371: 424–33.
12. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010; 363: 411–22.
13. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–54.
14. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013; 369: 213–23.
15. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol. 1991; 5: 1396–404.
16. Rundlett SE, Wu XP, Miesfeld RL. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol. Endocrinol. 1990; 4: 708–14.
17. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J. Biol. Chem. 1991; 266: 510–8.
18. Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem. Rev. 2005; 105: 3352–70.
19. McEwan IJ. Intrinsic disorder in the androgen receptor: identification, characterisation and drugability. Mol. BioSyst. 2012; 8: 82–90.
20. Jenster G, van der Korput HA, Trapman J, Brinkmann AO. Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J. Biol. Chem. 1995; 270: 7341–6.
21. Dehm SM, Regan KM, Schmidt LJ, Tindall DJ. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells. Cancer Res. 2007; 67: 10067–77.
22. Schaufele F, Carbonell X, Guerbadot M et al. The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci U S A 2005; 102: 9802–7.
23. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J. Biol. Chem. 1999; 274: 37219–25.
24. Sadar MD. Small molecule inhibitors targeting the “achilles’ heel” of androgen receptor activity. Cancer Res. 2011; 71: 1208–13.
25. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004; 10: 33–9.
26. Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995; 9: 401–6.
27. Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997; 57: 314–9.
28. Zhao XY, Malloy PJ, Krishnan AV et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 2000; 6: 703–6.
29. Sun C, Shi Y, Xu LL et al. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 2006; 25: 3905–13.
30. Fenton MA, Shuster TD, Fertig AM et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 1997; 3: 1383–8.
31. Yoshida T, Kinoshita H, Segawa T et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res. 2005; 65: 9611–6.
32. Korpal M, Korn JM, Gao X et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013; 3: 1030–43.
33. Taplin ME, Bubley GJ, Ko YJ et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999; 59: 2511–5.
34. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 2002; 277: 38087–94.
35. Agoulnik IU, Vaid A, Bingman WE 3rd et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005; 65: 7959–67.
36. Debes JD, Schmidt LJ, Huang H, Tindall DJ. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res. 2002; 62: 5632–6.
37. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res. 2003; 63: 7638–40.
38. Agoulnik IU, Vaid A, Nakka M et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006; 66: 10594–602.
39. Tien JC, Liu Z, Liao L et al. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res. 2013; 73: 3997–4008.
40. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J. Biol. Chem. 1999; 274: 7777–83.
41. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 2002; 277: 7076–85.
42. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66: 2815–25.
43. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68: 6407–15.
44. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008; 68: 4447–54.
45. Hu R, Dunn TA, Wei S et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69: 16–22.
46. Guo Z, Yang X, Sun F et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009; 69: 2305–13.
47. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008; 68: 5469–77.
48. Sun S, Sprenger CC, Vessella RL et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 2010; 120: 2715–30.
49. Hornberg E, Ylitalo EB, Crnalic S et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011; 6: e19059.
50. Zhang X, Morrissey C, Sun S et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 2011; 6: e27970.
51. Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther. Adv. Med. Oncol. 2014; 6: 167–79.
52. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502–12.
53. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513–20.
54. Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 2011; 8: 597–610.
55. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70: 7992–8002.
56. Thadani-Mulero M, Portella L, Sun S et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014; 74: 2270–82.
57. Mezynski J, Pezaro C, Bianchini D et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann. Oncol. 2012; 23: 2943–7.
58. Antonarakis ES, Lu C, Luber B et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015; 1: 582–91.
59. Pezaro CJ, Omlin AG, Altavilla A et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur. Urol. 2014; 66: 459–65.
60. van Soest RJ, van Royen ME, de Morree ES et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur. J. Cancer 2013; 49: 3821–30.
61. Li Z, Bishop AC, Alyamani M et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 2015; 523: 347–51.
62. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011; 364: 1995–2005.
63. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 2013; 368: 138–48.
64. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787–90.
65. Mostaghel EA, Marck BT, Plymate SR et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 2011; 17: 5913–25.
66. Cai C, Chen S, Ng P et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011; 71: 6503–13.
67. Chang KH, Li R, Kuri B et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013; 154: 1074–84.
68. Waltering KK, Urbanucci A, Visakorpi T. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol. Cell. Endocrinol. 2012; 360: 38–43.
69. Joseph JD, Lu N, Qian J et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013; 3: 1020–9.
70. Balbas MD, Evans MJ, Hosfield DJ et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013; 2: e00499.
71. Sahu B, Laakso M, Pihlajamaa P et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res. 2013; 73: 1570–80.
72. Arora VK, Schenkein E, Murali R et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309–22.
73. Isikbay M, Otto K, Kregel S et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm. Cancer 2014; 5: 72–89.
74. Venkitaraman R, Lorente D, Murthy V et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur. Urol. 2015; 67: 673–9.
75. Grindstad T, Andersen S, Al-Saad S et al. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS ONE 2015; 10: e0116691.
76. Yu Y, Liu L, Xie N et al. Expression and function of the progesterone receptor in human prostate stroma provide novel insights to cell proliferation control. J. Clin. Endocrinol. Metab. 2013; 98: 2887–96.
77. Kaarbo M, Mikkelsen OL, Malerod L et al. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol. 2010; 32: 11–27.
78. Carver BS, Chapinski C, Wongvipat J et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575–86.
79. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009; 15: 4799–805.
80. Kato M, Banuelos CA, Imamura Y et al. Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer. Clin. Cancer Res. 2016; 22: 2744–54.
81. Williamson SR, Zhang S, Yao JL et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod. Pathol. 2011; 24: 1120–7.
82. Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–8.
83. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur. Urol. 2004; 45: 586–92; discussion 592.
84. Epstein JI, Amin MB, Beltran H et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 2014; 38: 756–67.
85. Akamatsu S, Wyatt AW, Lin D et al. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Rep. 2015; 12: 922–36.
86. Yuan TC, Veeramani S, Lin MF. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr. Relat. Cancer 2007; 14: 531–47.
87. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann. Oncol. 2013; 24: 1802–7.
88. Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann. Oncol. 2013; 24: 1807–12.
89. Badrising S, van der Noort V, van Oort IM et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014; 120: 968–75.
90. Bianchini D, Lorente D, Rodriguez-Vida A et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur. J. Cancer 2014; 50: 78–84.
91. Schrader AJ, Boegemann M, Ohlmann CH et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur. Urol. 2014; 65: 30–6.
92. Nelson PS, Clegg N, Arnold H et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 2002; 99: 11890–5.
93. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 2005; 23: 8253–61.
94. Hu R, Lu C, Mostaghel EA et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012; 72: 3457–62.
95. Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell. Mol. Life Sci. 2011; 68: 3971–81.
96. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013; 73: 483–9.
97. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014; 371: 1028–38.
98. Antonarakis ES, Lu CX, Chen Y et al. AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2015; 33(Suppl): 138.
99. Fujimoto N. Novel agents for castration-resistant prostate cancer: early experience and beyond. Int. J. Urol. 2016; 23: 114–21.
100. Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol. Med. 2015; 7: 878–94.
101. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012; 72: 1494–503.
102. Foster WR, Car BD, Shi H et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011; 71: 480–8.
103. Fizazi K, Albiges L, Loriot Y, Massard C. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev. Anticancer Ther. 2015; 15: 1007–17.
104. Moilanen AM, Riikonen R, Oksala R et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci. Rep. 2015; 5: 12007. doi:10.1038.
105. Toren PJ, Kim S, Pham S et al. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol. Cancer Ther. 2015; 14: 59–69.
106. Moore WR, Norris JD, Wardell S et al. Direct effects of the selective CYP17 lyase (L) inhibitor, VT-464, on the androgen receptor (AR) and its oral activity in an F876L tumor mouse xenograft model. J. Clin. Oncol. 2015; 33: 263.
107. Njar VC, Brodie AM. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J. Med. Chem. 2015; 58: 2077–87.
108. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin. Cancer Res. 2014; 20: 4075–85.
109. Yaqub F. Galeterone activity in castration-resistant prostate cancer. Lancet Oncol. 2015; 16: e10.
110. Liu C, Lou W, Zhu Y et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin. Cancer Res. 2014; 20: 3198–210.
111. Andersen RJ, Mawji NR, Wang J et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010; 17: 535–46.
112. Myung JK, Banuelos CA, Fernandez JG et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Invest. 2013; 123: 2948–60.
113. De Mol E. Structure, dynamics and interactions of the N-terminal domain of the androgen receptor. 2014. [Cited 2 Jun 2016.] Available from URL: http://hdl.handle.net/10803/147275
114. Montgomery RB, Antonarakis ES, Hussain M et al. A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. J. Clin. Oncol. 2015; 33(Suppl): abstr TPS5072.
115. Sadar MD. Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. World J. Urol. 2012; 30: 311–8.
116. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012; 72: 4875–82.
117. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat. Rev. Clin. Oncol. 2014; 11: 129–44.
118. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306–13.
119. Roudier MP, True LD, Higano CS et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum. Pathol. 2003; 34: 646–53.
120. Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther. Adv. Urol. 2014; 6: 3–14.
121. Saad F, Fizazi KS. Androgen deprivation therapy and secondary hormone therapy in the management of hormone-sensitive and castration resistant prostate cancer. Urology 2015; 86: 852–61.
122. Gleghorn JP, Pratt ED, Denning D et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010; 10: 27–9.
123. Harouaka R, Kang Z, Zheng SY, Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol. Ther. 2014; 141: 209–21.
124. Alix-Panabieres C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 2012; 63: 199–215.
125. Zieglschmid V, Hollmann C, Bocher O. Detection of disseminated tumor cells in peripheral blood. Crit. Rev. Clin. Lab. Sci. 2005; 42: 155–96.
126. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008; 14: 6302–9.
127. Evans MJ. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012; 2: 985–94.
128. Dehdashti F, Picus J, Michalski JM et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur. J. Nucl. Med. Mol. Imaging 2005; 32: 344–50.
129. Larson SM, Morris M, Gunther I et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J. Nucl. Med. 2004; 45: 366–73.
130. Vargas HA, Wassberg C, Fox JJ et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 2014; 271: 220–9.
131. Zanzonico PB, Finn R, Pentlow KS et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J. Nucl. Med. 2004; 45: 1966–71.
132. Beattie BJ, Smith-Jones PM, Jhanwar YS et al. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J. Nucl. Med. 2010; 51: 183–92.
133. Evans MJ, Smith-Jones PM, Wongvipat J et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011; 108: 9578–82.
134. Chen Y, Foss CA, Byun Y et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J. Med. Chem. 2008; 51: 7933–43.
135. Hillier SM, Maresca KP, Femia FJ et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009; 69: 6932–40.
136. Rowe SP, Macura KJ, Ciarallo A et al. Comparison of PSMA-based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Sensitive and Castration-Resistant Metastatic Prostate Cancer. J. Nucl. Med. 2015; 57: 46–53.
137. Ulmert D, Evans MJ, Holland JP et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012; 2: 320–7.
138. Lepin EJ, Leyton JV, Zhou Y et al. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur. J. Nucl. Med. Mol. Imaging 2010; 37: 1529–38.
139. Leyton JV, Olafsen T, Lepin EJ et al. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin. Cancer Res. 2008; 14: 7488–96.
140. Imamura Y, Tien AH, Jian KZ et al. Development of an imaging approach to detect splice variants of androgen receptor in prostate cancer. J. Clin. Oncol. 2015; 33(Suppl): abstr 5058.